🟢 Insulet is trading 5.9% up in pre-market after Q3 results beat expectations

Insulet is trading at $164.00, up 5.90% in pre-market on November 4, 2026, after third-quarter results beat Wall Street expectations.

• Revenue was $842.0 million, and adjusted earnings were $1.99 per share, versus analysts’ expected $1.59.
• Insulet raised its full-year revenue and adjusted operating margin outlook and authorized a $1 billion share repurchase program.